Newsletter | June 7, 2021

06.07.21 -- Evolving Biosafety Testing To Meet The Needs Of Biologics Manufacturers

Alternatives To In Vivo Assays For Biosafety Testing Of Biologics

Even as alternative methods, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) have emerged, in vivo tests have stubbornly remained a central part of testing. This article examines current in vivo methods and explores modern alternatives.

How Biosafety Testing Will Evolve To Meet The Needs Of Biologics Manufacturers Tomorrow

Where we see almost daily innovation in production technologies, many of the methods used for biosafety testing are decades old. This webinar explores how new methods can be used to accelerate biosafety testing today.

Product Characterization: Reveal Your Molecule Earlier, Faster, And With Accuracy
Product characterization can be challenging throughout drug development because it requires advanced technologies and specialized expertise. Thus, it is vital to start product characterization early and use it throughout all phases of the drug manufacturing process.
Not Everyone Loves Surprises: Know Your ADC’s Critical Quality Attributes

The highly targeted approach of antibody-drug conjugates (ADCs), where an antibody is connected to an antitumor cytotoxin via a linker, has been extremely effective in treating various types of cancer. Combatting the challenges of developing and manufacturing ADCs requires robust product characterization throughout all phases of development.